Clinical efficacy and safety of P-15 peptide enhanced bone graft substitute in surgical bone regenerative procedures in adult maxillofacial, spine, and trauma patients
Open Access
- 4 February 2025
- journal article
- review article
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (2) , 77-92
Abstract
Aims: Autologous bone graft (ABG) is considered the ‘gold standard’ among graft materials for bone regeneration. However, complications including limited availability, donor site morbidity, and deterioration of regenerative capacity over time have been reported. P-15 is a synthetic peptide that mimics the cell binding domain of Type-I collagen. This peptide stimulates new bone formation by enhancing osteogenic cell attachment, proliferation, and differentiation. The objective of this study was to conduct a systematic literature review to determine the clinical efficacy and safety of P-15 peptide in bone regeneration throughout the skeletal system.Methods: PubMed, Embase, Web of Science, and Cochrane Library were searched for relevant articles on 13 May 2023. The systematic review was reported according to the PRISMA guidelines. Two reviewers independently screened and assessed the identified articles. Quality assessment was conducted using the methodological index for non-randomized studies and the risk of bias assessment tool for randomized controlled trials.Results: After screening, 28 articles were included and grouped by surgical indication, e.g. maxillofacial procedures (n = 18), spine (n = 9), and trauma (n = 1). Published results showed that P-15 peptide was effective in spinal fusion (n = 7) and maxillofacial (n = 11), with very few clinically relevant adverse events related to P-15 peptide.Conclusion: This systematic literature review concluded that moderate- (risk of bias, some concern: 50%) to high-quality (risk of bias, low: 46%) clinical evidence exists showing equivalent safety and efficacy in bone regeneration using a P-15 peptide enhanced bone graft substitute compared to ABG. P-15 peptide is safe and effective, resulting in rapid bone formation with a low probability of minor complications.Cite this article: Bone Joint Res 2025;14(2):77–92.Keywords
This publication has 62 references indexed in Scilit:
- Autologous bone graft: Is it still the gold standard?Injury, 2021
- Bone regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells current stage and future perspectivesBiomaterials, 2018
- P15 peptide stimulates chondrogenic commitment and endochondral ossificationInternational Orthopaedics, 2017
- A Review and Analysis of the YODA Trials: What Can We Glean Clinically?Current Reviews in Musculoskeletal Medicine, 2014
- The effect of collagen I mimetic peptides on mesenchymal stem cell adhesion and differentiation, and on bone formation at hydroxyapatite surfacesBiomaterials, 2009
- Clinical evaluation of anorganic bovine-derived hydroxyapatite matrix/cell-binding peptide (P-15) in the treatment of human infrabony defectsClinical Oral Investigations, 2008
- Bone and Bone Graft HealingOral and Maxillofacial Surgery Clinics of North America, 2007
- P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trialInternational Orthopaedics, 2006
- Bioactivation of an anorganic bone matrix by P-15 peptide for the promotion of early bone formationBiomaterials, 2005
- Enhanced cell attachment to anorganic bone mineral in the presence of a synthetic peptide related to collagenJournal of Biomedical Materials Research, 1996